This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Oct 6, 2025
•
7 min read
🧬 Cidara lands up to $339M BARDA contract for non-vaccine flu prevention, Ovid reports positive Ph1 data in drug-resistant epilepsy, FDA launches generics priority review program for domestic manufacturing, GSK comes out on top in UK PMCPA marketing scuffle, Palisade Bio closes $138M public offering fuelling IBD ambitions
Oct 3, 2025
9 min read
🧬 Jazz Pharma + PharmaMar's Zepzelca approved for first-line maintenance treatment in extensive-stage small-cell lung cancer, Cartography's $67M Series B in pursuit of “differentiated” cancer drugs, Amgens touts "landmark" Ph3 win for PCSK9 inhibitor in cardiovascular event prevention, Pfizer + C4 Therapeutics sign clinical trial + supply agreement, Vaxcyte's up to $1B Thermo Fisher deal for fill-finish space access, Daiichi Sankyo opens third international R&D site (this one in San Diego)
Oct 2, 2025
8 min read
🧬 Who's who of big pharma pools data in bid for better AI models, Halozyme expands subcutaneous delivery reach with up to $900M Elektrofi acquisition, AbbVie unveils $70M investment in Massachusetts bioresearch center, Ansa's $54.4M Series B to fuel DNA synthesis ambitions, Novartis nabs FDA approval first in oral BTK blocker for chronic spontaneous urticaria, Trump admins delays 100% tariff on branded pharmaceuticals
Oct 1, 2025
🧬 Pfizer first to embrace MFN drug pricing + DTC via upcoming "TrumpRx" website, Merck & Co. published positive Winrevair Ph3 data in pulmonary arterial hypertension, Barinthus Therapeutics + Clywedog Therapeutics reverse merger, Rovi to acquire Phoenix-based BMS facility, AstraZeneca to "harmonize its share listing structure" via direct NYSE listing, EMA publishes draft guidance on including patient perspective in drug approval process
Sep 30, 2025
11 min read
🧬 Genmab ponies up $8B for Merus acquisition - eyes bispecific cancer assets, AstraZeneca + Daiichi Sankyo's Enhertu ADC beats Roche's Kadcyla in early breast cancer trial, Gilead in-licenses Health Hope Pharma's P-gp inhibitor in virology space for $10M upfront + $72.5M biobucks, FDA approves J&J's Tremfya in pediatric plaque psoriasis, Star Therapeutics lands $125M Series D for bleeding disorder aspirations, Full-Life Technologies $77M Series C + debt financing for radiopharma aspirations
Sep 29, 2025
🧬 AstraZeneca joins direct-to-consumer fray with Oct 1 platform launch, Sanofi caps all insulin products in the US to $35/month (regardless of insurance), Amgen commits $650M to Puerto Rico site expansion, Eli Lilly opens biotech incubator in San Diego (able to fit up to 15 companies & 250 employees), Lotus buys-out Alvogen for up to $2B, Cure Alzheimer's Fund receives $50M gift to support research, FDA approves Regeneron's ANGPTL3 antibody to treat children 1 - 5 years of age with homozygous familial hypercholesterolemia
Sep 26, 2025
🧬 FDA draft docs for faster CGT drug development, Eli Lilly lands a pair of approvals (FDA approval for oral SERD in breast cancer + EC approval for Kisunla in early symptomatic Alzheimer's), Merck & Co. in-licenses Evaxion's AI-platform based vaccine candidate for $7.5M upfront + $592M biobucks, NIH pledges $87M for organoid center in accelerating shift away from animal testing, UK may attempt big pharma damage control by "fix[ing] the commercial environment" (raising prescription drug prices)
Sep 25, 2025
🧬 uniQure's Huntington's gene therapy slows down disease progression by 75% over 3 years in Ph2 trial, Glenmark signs up to $1B ADC deal with Hengrui Pharma, Roche presents new Ocrevus data with "significant benefit" in preventing MS-related disability progress, Moderna opens new UK vaccine manufacturing/R&D site amongst other big pharma exits, Fujifilm Biotechnologies opens doors to new $3.2B facility as one of the "largest cell culture biomanufacturing sites in the U.S.", Sparrow Pharmaceuticals lands $95M Series B to help T2D patients with elevated cortisol
Sep 24, 2025
10 min read
🧬 Eli Lilly drops $6.5B on Houston API plant, BMS' multiple myeloma protein degrader iberdomide hits a Ph3 goal, Merck & Co. commits further $349M into Variational AI drug discovery partnership, atai Life Sciences & Beckley Psytech report positive Ph2a data for DMT analog in treatment resistant depression, Sanofi commits further $625M into venture investment arm Sanofi Ventures, Manas AI touts $26M seed extension for "full-stack, AI native drug discovery and development"
Sep 23, 2025
🧬 Pfizer's $4.9B obesity play with Metsera acquisition, Avenzo Tx's $60M Series B for "best-in-class oncology drug", Until's organ cryopreservation ambitions lead to $58M Series A, Roche posts Ph3 win for oral selective estrogen receptor degrader in breast cancer, Ionis' Alexander disease antisense oligonucleotide Phase 3 win, Trump admin continues baffling everyone - now linking Tylenol use in pregnancy to autism
Sep 22, 2025
🧬 Merck & Co.'s Keytruda gets subcutaneous FDA ok, Novo Nordisk's once-weekly Type 2 diabetes combo-therapy lands CHMP nod, Merck KGaA opens €150m "climate-neutral" Cork Ireland facility, Eli Lilly plans orforglipron launch in India (citing no cold chain required versus weight-loss injectables), AusperBio lands $63M Series B2 towards chronic hep B functional cures, "bombardment of [Facebook] spam" lands Eli Lilly in UK marketing watchdog hot water
Sep 20, 2025
14 min read
Hot takes on value creation in biotech
